Yongzhi Lu

机构：Guangzhou Institutes of Biomedicine and Health, Guangzhou Experimental Station, First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Medical University · ORCID：0000-0002-9985-8546

发表论文 67 篇 · 总被引 1384 次 · h-index 21

代表论文

• Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19 (2024 · Nature Communications · 被引 34)
• Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein (2024 · Signal Transduction and Targeted Therapy · 被引 28)
• Advances in the Understanding of Two-Pore Domain TASK Potassium Channels and Their Potential as Therapeutic Targets (2022 · Molecules · 被引 18)
• SMARCA4 mutations and expression in lung adenocarcinoma: prognostic significance and impact on the immunotherapy response (2024 · FEBS Open Bio · 被引 9)
• A small-molecule Skp1 inhibitor elicits cell death by p53-dependent mechanism (2022 · iScience · 被引 9)
• Asperdoles A–N: Indole Diterpenoids from the Endolichenic Fungus Aspergillus sp. TJ403-YJ22 (2025 · Journal of Natural Products · 被引 4)